Have you ever wondered about how CCF engages with Industry Partners? Watch our webinar, recorded on May 27th, to learn about the partnerships and collaboration we have with industry.
QED Therapeutics, Servier Pharmaceuticals, Taiho, Incyte and Zymeworks will share how they serve cholangiocarcinoma patients.
Taiho Oncology is a different kind of pharmaceutical company. We have deep roots and unmatched corporate agility that enable us to fulfill our purpose – making a better world for cancer patients and the people who care for them. Our corporate philosophy is “We strive to improve human health and contribute to a society enriched by smiles.”
As Director of Patient Alliances and Public Relations at Taiho Oncology, Inc. Kimberly Hart leads patient advocacy engagement for the company, along with corporate public relations activities. With over 25 years in the Pharmaceutical Industry, Kim has a broad understanding of drug development, strategic and tactical planning, along with global experience with diverse groups, overseeing complex programs and teams. Her international experience includes positions with Merck KGaA in Darmstadt, Germany as Head of Medical Publications, Oncology and Helsinn Healthcare SA as Associate Director, Patient Advocacy.
At Servier Pharmaceuticals, we are dedicated to bringing the promise of tomorrow to the patients we serve.
We are a commercial stage, privately held United States pharmaceutical company. Launched by Servier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of a biotech.
Susan Stein, MPH, Director, Oncology Patient Advocacy at Servier Pharmaceuticals
Passionate about health and wellness, Susan is a tireless advocate for advancing patient care, especially in oncology and rare disease where she has spent the past dozen years of her career. She will always bring the patient voice and insights to internal discussions and organizational decision-making.
Susan has worked with the world’s most innovative companies to assist them in bringing therapies to market for underserved populations. With her heart in public health, Susan is driven to bring patient access, health equity, policy, and education to these same discussions. Susan is happily married and the very proud mom of two sons.
Zymeworks, globally headquartered in Vancouver, Canada, is a clinical-stage biotechnology company engineering and developing best-in-class, multifunctional, antibody-based therapies precisely engineered to provide powerful new treatments for cancers and other serious illnesses. Zymeworks’ clinical pipeline is currently focused on bispecific antibodies and antibody-drug conjugates (ADCs) for the treatment of HER2-expressing cancers, including biliary tract, (also known as cholangiocarcinoma), gastric, breast and other solid tumor cancers.
Mary Klem is head of Corporate Communications for Zymeworks, responsible for advocacy relations, media relations, disease awareness, industry relations, and internal communications. Mary joined Zymeworks in September of 2020 and recently relocated from Southern California to Seattle, where Zymeworks’ U.S. headquarters are based. She has more than 35 years of professional communications experience, including 17 years in various roles in Corporate Affairs at Amgen and 10 years in Corporate Communications at Levi Strauss & Co. Mary holds a degree in journalism and public relations from the University of Oregon.
A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and conditions. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.
With singular focus, QED is devoted to the development of our investigational candidate, infigratinib. A first-in-class, selective, tyrosine kinase inhibitor, infigratinib has promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.
Anne is the Director of Patient Advocacy for QED Therapeutics, an affiliate of BridgeBio Pharma. In her role, Anne is responsible for ensuring that the voice of those living with FGFR-driven disorders, such as cholangiocarcinoma, urothelial cancer, and achondroplasia, are included and reflected globally in QED’s studies and work efforts. In her prior experience, Anne served as the Director of Programs for Can Do MS, a health and wellness non-profit delivering programs and resources for families living with multiple sclerosis. She brings more than 20 years of experience in education and program development, having worked as a high school math teacher, as well as developing CME/CE programs for healthcare providers in cardiology and pharmacy. In her free time, you can find Anne planning her next (long-awaited!) travel adventure, experimenting new recipes in the kitchen, and skiing fresh powder.
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Jenifer Antonacci is an award-winning communications and public relations expert and passionate advocate for patients. At Incyte, Jen leads the Public Affairs team in North America, including brand and disease education communications and engagement with patient communities with the goal of advancing understanding, awareness and scientific research. Prior to joining Incyte, Jen worked at other leading biopharmaceutical companies including Pfizer, Cephalon, and Wyeth.